Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease (ASUCOV)
A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy of Asunercept for the Treatment of Hospitalized Patients With Moderate to Severe COVID 19 Disease
Sponsor: Apogenix GmbH
Terminated
Lack of patients
Listed as NCT05639192, this PHASE3 trial focuses on COVID-19 and remains terminated or withdrawn. Sponsored by Apogenix GmbH, it has been updated 7 times since 2022, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Sep 2023 — Jul 2024 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
Apr 2023 — Aug 2023 [monthly]
Recruiting PHASE3
-
Jan 2023 — Apr 2023 [monthly]
Recruiting PHASE3
First recorded
Nov 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Apogenix GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alicante, Spain , Amiens, France , Aurangabad, India , Bangalore, India , Barcelona, Spain , Benoni, South Africa , Bolesławiec, Poland , Brive-la-Gaillarde, France , Cologne, Germany , Durban, South Africa and 23 more locations